TRAX Surges 21% on Eve of Celiac Trial Results — But Can a 30-Patient Study Justify a Billion-Dollar Bet?

Shares of First Tracks Biotherapeutics rocketed 20.9% to $38.50 in pre-market trading as investors positioned ahead of the company's most important milestone since spinning off from AnaptysBio in April: top-line results from its celiac-disease drug trial, due this morning at 8:30 a.m. ET. The data hadn't dropped yet — making this a pure anticipation trade, and a risky one.

• A Tiny Trial Carrying an Outsized Burden. The Phase 1b trial enrolled just 30 patients in a randomized, placebo-controlled gluten-challenge study designed to test whether the drug can prevent intestinal damage over six weeks. That's a small sample on which to build conviction. Analysts estimate the drug represents roughly 95% of TRAX's valuation , meaning a miss would gut the stock. The company is clinical-stage, which generally implies higher risk and uncertainty regarding successful development and commercialization.

• Wall Street Already Priced In Optimism. Twelve analysts rate TRAX a Buy versus just one Hold and one Sell, with an average price target of $65.17.

Guggenheim initiated at Buy with a $100 target in September , while Piper Sandler sits at $95. Even after today's jump, the stock trades well below consensus — suggesting the Street sees blockbuster potential if the data cooperate. But that gap also means expectations are sky-high, leaving little margin for ambiguous results.

• No Approved Drugs Exist — That's the Opportunity and the Problem. Celiac disease is a chronic autoimmune disorder with no FDA-approved drug treatment; a gluten-free diet remains the only option, yet accidental exposure still causes intestinal injury.

The celiac drug market is valued at $1.42 billion in 2026 and projected to hit $2.57 billion by 2032. First-mover advantage is enormous, but competitors including Takeda, Amgen, Teva, and a dozen smaller biotechs are racing with their own candidates.

• A Young Company Burning Cash on a Countdown Clock. TRAX launched in April with $180 million in cash and a stated two-year runway.

It posted a net loss of $33.4 million in Q2 alone. Positive data today would strengthen its hand to raise capital on favorable terms or attract a partner; negative results would compress that runway dramatically as investors flee. The morning webcast isn't just a scientific update — it's effectively a verdict on whether TRAX, barely six months old as a public company, has a viable future.